Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

Contrast Induced Acute Kidney Injury Clinical Trial

Official title:

Effect on Contrast Induced Acute Kidney Injury of APX-115 in Subjects Undergoing Percutaneous Coronary Intervention A Randomized, Double-blind, Parallel Group, Multicenter, Multi-national Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05758896
• Other study ID #: A01-115-04
• Status: Recruiting
• Phase: Phase 2
• Start date: December 27, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: January 2024
• Source: Aptabio Therapeutics, Inc.
• Contact: Aptabio Therapeutics Inc.
• Phone: +82313653693
• Email: cd[@]aptabio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 280 patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib hydrochloride) or placebo arm.

Description:

Patients with chronic kidney disease undergoing percutaneous coronary intervention deserve careful consideration of various clinical options to minimize the risk of contrast-induced acute kidney injury and to optimize clinical outcomes. Contrast-induced acute kidney injury (CI-AKI) is a leading cause of a hospital-acquired renal failure and has been reported to affect both the mortality and morbidity of patients receiving contrast media. Contrast-induced acute kidney injury is the third leading cause of hospital-acquired acute kidney injury and has been recognized as a serious complication of percutaneous coronary intervention (PCI), which may be associated with increased morbidity and mortality. APX-115 is a potent small molecule inhibitor of NADPH-oxidase (NOX) isozymes developed by AptaBio Therapeutics, Inc. In-vivo study results suggest that multiple NOX isoforms may contribute to renal injury in CI-AKI model, and pan-NOX inhibition may be a new therapeutic approach for prevention of CI-AKI.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 280
• Est. completion date: December 31, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willing and able to provide informed consent.

2. Male or female, of any race or ethnicity, 18 years of age or older, inclusive, on the day of informed consent. Racial and ethnic minorities should be included in the study population to the greatest extent possible.

3. Diagnosed with coronary artery disease.

4. Planned to undergo coronary angiography within 4 weeks of being consented.

5. Risk of CKD evidenced by 30 mL/min/1.73m2 = eGFR (Glomerular filtration rate) < 90 mL/min/1.73 m2 confirmed by local or central laboratory.

6. Women of childbearing potential or males willing and able to use at least one protocol-specified method of contraception for the duration of their enrolment.

7. Subject is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the ICF.

Exclusion Criteria:

1. Females who are pregnant or who are planning to become pregnant before the end of planned enrolment or who are breastfeeding.

2. Subjects who are not expected to go through PCI at the discretion of investigator or cardiologist

3. Subjects who have a history of hypersensitivity to contrast media or who cannot be administered contrast media according to investigator's discretion

4. Acute myocardial infarction within 1 month prior to Screening

5. ESRD confirmed by eGFR < 15 mL/min/1.73 m2 at Screening.

6. Clinically significant heart disease as determined by the Investigator within 2 months prior to Screening including but not limited to any of following; cardiogenic shock, treatment requiring intra-aortic balloon pump (IABP) support, treatment with extra corporeal membrane oxygenation (ECMO), or NYHA class IV heart failure.

7. Uncontrolled treated/untreated hypertension (defined as systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg, mean of measured 2 times at Screening will be permitted).

8. Known or suspected hypersensitivity to any component of the APX-115 formulation.

9. History of acute kidney injury or renal dialysis within 1 month prior to Screening and/or plan to undergo a renal dialysis during enrolment.

10. Clinically apparent liver disease as determined by the Investigator (e.g., jaundice, cholestasis, hepatic synthetic impairment, or active hepatitis) or moderate or severe hepatic impairment as determined by Child-Pugh score (Class B or C) at Screening.

11. Impaired liver function, defined as alanine aminotransferase (ALT) = 2.5 times UNL or Total bilirubin >1.5 × ULN, unless the subject has known Gilbert's syndrome.

12. Any sign or symptom of acute or chronic infection at Screening.

13. Receipt of any investigational drug within 4 weeks prior to Screening.

14. Confirmed or suspected abuse of alcohol or controlled substances within 1 year prior to Screening.

15. Clinically significant hematology abnormalities; hemoglobin <9 g/dL for females or <11 g/dL for males, absolute neutrophil count <1500/mm3, platelet count <100 × 109/L) at Screening. If any parameter is below the specified threshold, one hematology retest analyzed at the central or local laboratory within a week prior to randomization is permitted with the result of the last sample being conclusive.

16. Any other clinically significant medical condition or laboratory abnormality as determined by the Investigator that might jeopardize the safety of the subject, impair subject compliance, or impede safety/efficacy observations during enrolment.

17. Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation with protocol requirements

18. Use of CYP1A2, CYP2B6 and CYP3A4 substrates or UGT inhibitors and inducers or OAT3 substrates prior to enrollment or concurrently. It will be only accepted to be eligible to screening if the subjects' concomitant medications will be reviewed and approved by the medical monitor and/or sponsor prior to the initial study dose

Related Conditions & MeSH terms

• Acute Kidney Injury
• Contrast Induced Acute Kidney Injury
• Wounds and Injuries

Intervention

Drug:
• Isuzinaxib (APX-115)
Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
• Placebo
Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo

Locations

Country	Name	City	State
Korea, Republic of	Kangwon National University Hospital	Chuncheon
Korea, Republic of	Keimyung University Dongsan Hospital	Daegu
Korea, Republic of	Chungnam National University Hospital	Daejeon
Korea, Republic of	Inje University Ilsan Paik Hospital	Goyang
Korea, Republic of	Chonnam National University Hospital	Gwangju
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam-si
Korea, Republic of	Kangbuk Samsung Hospital	Seoul
Korea, Republic of	Korea University Anam Hospital	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	The Catholic University of Korea Seoul St. Mary's Hospital	Seoul
Korea, Republic of	The Catholic University of Korea St. Vincent's Hospital	Suwon
Korea, Republic of	Ulsan University Hospital	Ulsan
United States	Florida Cardiovascular Research	Hialeah	Florida
United States	Sarkis Clinical Trials	Ocala	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Aptabio Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Biomarkers assessment	NGAL, KIM-1, Cystatin-C and NT-proBNP	72 hours
Other	Composite PCI outcome	death, myocardial infarction (MI) and stent thrombosis (ST)	over 12-week period
Primary	Safety endpoints: adverse event	Number of adverse events	Day -2 to day 84
Primary	Safety endpoints: vital sign	Number of subjects with abnormal Vital Signs	Day 0 to day 84
Primary	Safety endpoints: physical exam	Abnormal physical examination	Day 0 to day 84
Primary	Safety endpoints: ECG	Abnormal Electrocardiogram (ECG)	Day 0 to day 84
Primary	Safety endpoints: labs	Number of abnormal results of Hematology, Biochemistry and Urinalysis	Day 0 to day 84
Secondary	Incidence rate of Acute kidney injury	definition of CI-AKI: Serum Creatinine absolute variation = 0.5mg/dL or Serum creatinine relative variation increasing 25% from baseline up to 72 hours after CAG with the exposure of contrast medium and PCI	from baseline up to 72 hours after PCI procedure
Secondary	Long term kidney function: Serum creatinine	Serum creatinine level	week 4 and week 12
Secondary	Long term kidney function: eGFR	eGFR level	week 4 and week 12
Secondary	Kidney function parameters: creatinine, BUN	Serum creatinine and BUN level	over 12-week period
Secondary	Kidney function parameters: eGFR	eGFR using CKD-EPI	over 12-week period
Secondary	pharmacokinetics parameters: the area under the plasma concentration-time curve (AUC0-last, AUCtau)	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: peak concentration (Cmax, Tmax)	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: steady state peak plasma concentration (Css,max)	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: steady state trough plasma concentration (Css,min)	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: steady state after 5 consecutive days of drug administration	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: apparent total clearance (CL/F)	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: renal clearance (CLR)	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: apparent nonrenal clearance (CLNR/F)	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: apparent volume of distribution (V/F)	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: terminal half-life (t1/2)	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2
Secondary	pharmacokinetics parameters: fraction/cumulated fraction of excreted in urine	to be assessed from plasma and urine samples (subset of subjects only)	Day -2~2